SCHEMBL24671043

SCHEMBL24671043

Nc1ccc(-c2cccc3c2OCCC3)c(I)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 2/20 0.35
PARP1 P09874 1/20 0.33
CDK2 P24941 1/20 0.33
CDK9 P50750 1/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
HTR2B P41595 1/20 0.33
ACHE P22303 4/20 0.31
GRIN2D O15399 1/20 0.31
GRIN3B O60391 1/20 0.31
GRIN1 Q05586 1/20 0.31
GRIN2A Q12879 1/20 0.31
GRIN2B Q13224 1/20 0.31
GRIN2C Q14957 1/20 0.31
GRIN3A Q8TCU5 1/20 0.31
NOS2 P35228 1/20 0.30
HASPIN Q8TF76 1/20 0.30
HCRTR1 O43613 1/20 0.30
HCRTR2 O43614 1/20 0.30
HTR1A P08908 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29495812 0.86 PARP1 (0.35) NOS3PARP1CDK2CDK9ACHE
SCHEMBL22969433 0.86 PARP1 (0.35) NOS3PARP1CDK2CDK9ACHE
SCHEMBL22969570 0.82 CDK2 (0.36) NOS3PARP1CDK2CDK9ACHE
SCHEMBL29495957 0.82 CDK2 (0.36) NOS3PARP1CDK2CDK9ACHE
SCHEMBL22969403 0.77 PARP1 (0.43) NOS3PARP1GRIN2DGRIN3BGRIN1
SCHEMBL29495954 0.77 PARP1 (0.43) NOS3PARP1GRIN2DGRIN3BGRIN1
SCHEMBL29496081 0.73 CDK2 (0.35) NOS3PARP1CDK2CDK9ACHE
SCHEMBL3396520 0.69 ADORA2A (0.36) NOS3PARP1CDK2CDK9ACHE
SCHEMBL20870689 0.69 PARP1 (0.41) PARP1HTR2AHTR2CHTR2BHTR1A
SCHEMBL6584391 0.69 PARP1 (0.44) NOS3PARP1ACHEHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220298135-A1 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS DOMAIN THERAPEUTICS (FR) 2022-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220298135-A1 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS NPFFR2, NPFFR1, OPRL1 NOS3 899/4885PARP1 3040/4885CDK2 3050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.